Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Intervention not reported
APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation
1 finding from 1 review
Short‐term NACE · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial probably leads to lower short‐term NACE compared with transfemoral approach (moderate certainty).
1 finding from 1 review
Short‐term cardiac death · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial probably leads to lower short‐term cardiac death compared with transfemoral approach (moderate certainty).
1 finding from 1 review
Short‐term MI · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial showed no clear difference in short‐term MI compared with transfemoral approach (high certainty).
1 finding from 1 review
Success of the procedure · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial probably leads to lower success of the procedure compared with transfemoral approach (moderate certainty).
1 finding from 1 review
Short‐term all‐cause mortality · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial leads to lower short‐term all‐cause mortality compared with transfemoral approach (high certainty).
1 finding from 1 review
Bleeding · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial may leads to lower bleeding compared with transfemoral approach (low certainty).
1 finding from 1 review
Access site complications · people with coronary artery disease undergoing diagnostic coronary angiography and percutaneous coronary intervention
Transradial may leads to lower access site complications compared with transfemoral approach (low certainty).
1 finding from 1 review
All‐cause death: not measured · patients with restenosis after percutaneous coronary intervention in coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Restenosis Coronary angiography · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower restenosis Coronary angiography compared with conventional western medicine (CWM) plus placebo (high certainty).
1 finding from 1 review
Recurrence angina pectoris with 1 month · patients with restenosis after percutaneous coronary intervention in coronary heart disease
Xiongshao capsule (XSC) plus conventional western medicine (CWM) leads to lower recurrence angina pectoris with 1 month compared with conventional western medicine (CWM) plus placebo (high certainty).
3 findings from 1 review
RR 0.31 [0.1, 0.92]
1 study · 314 participants
High
RR 0.37 [0.19, 0.71]
1 study · 314 participants
High
RR 0.26 [0.18, 0.38]
2 studies · 432 participants
High
Health‐related quality of life: not measured · patients with restenosis after percutaneous coronary intervention in coronary heart disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found